These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 26965935)

  • 1. Long-Term Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy in the Young and the Elderly.
    Liebregts M; Steggerda RC; Vriesendorp PA; van Velzen H; Schinkel AF; Willems R; van Cleemput J; van den Berg MP; Michels M; ten Berg JM
    JACC Cardiovasc Interv; 2016 Mar; 9(5):463-9. PubMed ID: 26965935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy.
    Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Januska J; Krejci J; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Bundgaard H; Ten Berg JM; Veselka J
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1134-1143. PubMed ID: 28595881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long-Term Follow-Up Study Based on the Euro-Alcohol Septal Ablation Registry.
    Veselka J; Faber L; Liebregts M; Cooper R; Januska J; Krejci J; Bartel T; Dabrowski M; Hansen PR; Almaas VM; Seggewiss H; Horstkotte D; Adlova R; Bundgaard H; Ten Berg J; Stables RH; Jensen MK
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28512112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Septal Thickness on the Clinical Outcome After Alcohol Septal Alation in Hypertrophic Cardiomyopathy.
    Jensen MK; Jacobsson L; Almaas V; van Buuren F; Hansen PR; Hansen TF; Aakhus S; Eriksson MJ; Bundgaard H; Faber L
    Circ Cardiovasc Interv; 2016 Jun; 9(6):. PubMed ID: 27217377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Patients With Hypertrophic Obstructive Cardiomyopathy and Pacemaker Implanted After Alcohol Septal Ablation.
    Veselka J; Liebregts M; Cooper R; Faber L; Januska J; Kashtanov M; Tesarkova KH; Hansen PR; Seggewiss H; Shloydo E; Popov K; Hansvenclova E; Bonaventura J; Berg JT; Stables RH; Polakova E
    JACC Cardiovasc Interv; 2022 Oct; 15(19):1910-1917. PubMed ID: 36202559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes.
    Kimmelstiel C; Zisa DC; Kuttab JS; Wells S; Udelson JE; Wessler BS; Rastegar H; Kapur NK; Weintraub AR; Maron BJ; Maron MS; Rowin EJ
    Circ Cardiovasc Interv; 2019 Jul; 12(7):e007673. PubMed ID: 31296080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: outcomes in young, middle-aged, and elderly patients.
    Leonardi RA; Townsend JC; Patel CA; Wolf BJ; Todoran TM; Powers ER; Steinberg DH; Fernandes VL; Nielsen CD
    Catheter Cardiovasc Interv; 2013 Nov; 82(5):838-45. PubMed ID: 22936613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry.
    Veselka J; Jensen MK; Liebregts M; Januska J; Krejci J; Bartel T; Dabrowski M; Hansen PR; Almaas VM; Seggewiss H; Horstkotte D; Tomasov P; Adlova R; Bundgaard H; Steggerda R; Ten Berg J; Faber L
    Eur Heart J; 2016 May; 37(19):1517-23. PubMed ID: 26746632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Institutional Experience on Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy.
    Veselka J; Faber L; Jensen MK; Cooper R; Januska J; Krejci J; Bartel T; Dabrowski M; Hansen PR; Almaas VM; Seggewiss H; Horstkotte D; Adlova R; Bundgaard H; Ten Berg J; Liebregts M
    Can J Cardiol; 2018 Jan; 34(1):16-22. PubMed ID: 29275877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience.
    Steggerda RC; Damman K; Balt JC; Liebregts M; ten Berg JM; van den Berg MP
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1227-34. PubMed ID: 25326737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of septal reduction for obstructive hypertrophic cardiomyopathy.
    Sedehi D; Finocchiaro G; Tibayan Y; Chi J; Pavlovic A; Kim YM; Tibayan FA; Reitz BA; Robbins RC; Woo J; Ha R; Lee DP; Ashley EA
    J Cardiol; 2015 Jul; 66(1):57-62. PubMed ID: 25238885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and outcomes of alcohol septal ablation in the era of transcatheter valve interventions.
    Engel Gonzalez P; Gregerson S; Mahmood S; Brooks C; Villablanca PA; Frisoli TM; Lee J; Wyman JF; Wang DD; O'Neill WW; O'Neill BP
    Catheter Cardiovasc Interv; 2024 May; 103(6):1023-1034. PubMed ID: 38639143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical follow-up of patients undergoing percutaneous alcohol septal reduction for symptomatic obstructive hypertrophic cardiomyopathy.
    Fortunato de Cano S; Nicolas Cano M; de Ribamar Costa J; Alves Pinheiro J; Bellio de Mattos Barretto R; Costa de Souza Le Bihan D; Abizaid A; Sousa A; Eduardo Sousa J
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):953-960. PubMed ID: 27143093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation.
    Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Michels M; Bundgaard H; Ten Berg JM; Veselka J
    Europace; 2018 Sep; 20(FI2):f198-f203. PubMed ID: 29016960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy.
    Singh K; Qutub M; Carson K; Hibbert B; Glover C
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):107-15. PubMed ID: 26526299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrioventricular conduction after alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Axelsson A; Weibring K; Havndrup O; Kelbæk H; Jørgensen E; Helqvist S; Iversen K; Køber L; Bundgaard H; Jensen MK
    J Cardiovasc Med (Hagerstown); 2014 Mar; 15(3):214-21. PubMed ID: 24662414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low incidence of procedure-related major adverse cardiac events after alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy.
    Veselka J; Lawrenz T; Stellbrink C; Zemanek D; Branny M; Januska J; Groch L; Dimitrow P; Krejci J; Dabrowski M; Mizera S; Kuhn H
    Can J Cardiol; 2013 Nov; 29(11):1415-21. PubMed ID: 23927866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation.
    Kwon DH; Kapadia SR; Tuzcu EM; Halley CM; Gorodeski EZ; Curtin RJ; Thamilarasan M; Smedira NG; Lytle BW; Lever HM; Desai MY
    JACC Cardiovasc Interv; 2008 Aug; 1(4):432-8. PubMed ID: 19463341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender Disparities in Clinical Outcome After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy in the Chinese Han Population: A Cohort Study.
    Wang Y; Zhao HW; Wang CF; Meng QK; Cui CS; Zhang XJ; Zhu Y; Fan CY; Luo DF; Chen BJ; Luan B; Hou AJ
    Heart Lung Circ; 2020 Dec; 29(12):1856-1864. PubMed ID: 32611501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy.
    Vriesendorp PA; Liebregts M; Steggerda RC; Schinkel AF; Willems R; Ten Cate FJ; van Cleemput J; Ten Berg JM; Michels M
    JACC Heart Fail; 2014 Dec; 2(6):630-6. PubMed ID: 25447346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.